Contraceptive options and their associated estrogenic environmental loads: relationships and trade-offs

Estimating the eco-toxicological risk of estrogens in China's rivers using a high-resolution contaminant fate model

The contamination of freshwater systems arises in many river basins due to industrialization and population growth, posing risks to ecosystems and human health. Despite these concerns, the fate and potential impact of many emerging pollutants are currently unknown, especially when the compounds are released into surface waters from populations distributed across large spatial scales. In order to address this shortcoming, a spatially-explicit contaminant fate model was developed as an extension of the global, vector-based river routing model HydroROUT. HydroROUT operates at very high spatial resolution (∼500 m), simulates river and stream chemical transport with in-stream removal, and contains links to a set of lakes and reservoirs, which act as a partial sink during the transport. The chemical fate model was applied to China and includes a consumption and release module based on county-level population demographics, considers point-source contributions from 2547 wastewater treatment plants, and accumulates contributions of rural and urban populations not connected to sewage treatment plants. As a case study, the sources and fates of the estrogens estrone (E₁), 17β-estradiol (E₂), estriol (E₃), as well as the synthetic estrogenic steroid hormone 17α-ethinylestradiol (EE₂) were modelled in Chinese surface water bodies. Preliminary validation of the results showed predictions to be within the ranges of concentrations reported in literature, with exception of EE₂. The total estrogenic mass in the entire river and lake system amounted to 370 tonnes of estrogens, with about 1.3 tonnes per year discharged to the ocean, neighboring countries or to inland sinks. Under a selected baseline scenario, eco-toxicological risk-i.e., contaminant concentrations in excess of the predicted no effect concentration (PNEC)-is found in 23.6% of all analyzed rivers of China with an average flow > 0.1 m³/s. Out of these, about 4% of rivers showed a high level of risk of 10 times or more above PNEC. Medium-to-large rivers are disproportionally affected; for example, 23.6%, 37.3%, 29.0% and 21.6% of river length are at risk in rivers of 1-10, 10-100, 100-1,000, and 1,000-10,000 m³/s of discharge, respectively, whereas no risk was predicted in the largest rivers (i.e., >10,000 m³/s) of China. Wastewater treatment plants process 22.5% of the total hormone load and thus play an important role in water quality control by reducing the risk in substantial portions of the river network, which would otherwise show elevated risk. Releases from untreated population dominate by far the overall contribution to risk.

Risks and benefits related to alimentary exposure to xenoestrogens

Xenoestrogens are widely diffused in the environment and in food, thus a large portion of human population worldwide is exposed to them. Among alimentary xenoestrogens, phytoestrogens (PhyEs) are increasingly being consumed because of their potential health benefits, although there are also important risks associated to their ingestion. Furthermore, other xenoestrogens that may be present in food are represented by other chemicals possessing estrogenic activities, that are commonly defined as endocrine disrupting chemicals (EDCs). EDCs pose a serious health concern since they may cause a wide range of health problems, starting from pre-birth till adult lifelong exposure. We herein provide an overview of the main classes of xenoestrogens, which are classified on the basis of their origin, their structures and their occurrence in the food chain. Furthermore, their either beneficial or toxic effects on human health are discussed in this review.

Risks associated with the environmental release of pharmaceuticals on the U.S. Food and Drug Administration "flush list"

A select few prescription drugs can be especially harmful and, in some cases, fatal with just one dose when not used as prescribed. Therefore, the U. S. Food and Drug Administration (FDA) recommends that expired, unwanted, or otherwise unused portions of most of these drugs be disposed of quickly through a take-back program. If such an option is not readily available, FDA recommends that they be flushed down the sink or toilet. The goal of the current investigation was to evaluate the ecological and human-health risks associated with the environmental release of the 15 active pharmaceutical ingredients (APIs) currently on the FDA "flush list". The evaluation suggests that even when highly conservative assumptions are used-including that the entire API mass supplied for clinical use is flushed, all relevant sources in addition to clinical use of the API are considered, and no metabolic loss, environmental degradation, or dilution of wastewater effluents are used in estimating environmental concentrations-most of these APIs present a negligible eco-toxicological risk, both as individual compounds and as a mixture. For a few of these APIs, additional eco-toxicological data will need to be developed. Using similar conservative assumptions for human-health risks, all 15 APIs present negligible risk through ingestion of water and fish.

Pubertal Mammary Gland Development: Elucidation of In Vivo Morphogenesis Using Murine Models

During the past 25 years, the combination of increasingly sophisticated gene targeting technology with transplantation techniques has allowed researchers to address a wide array of questions about postnatal mammary gland development. These in turn have significantly contributed to our knowledge of other branched epithelial structures. This review chapter highlights a selection of the mouse models exhibiting a pubertal mammary gland phenotype with a focus on how they have contributed to our overall understanding of in vivo mammary morphogenesis. We discuss mouse models that have enabled us to assign functions to particular genes and proteins and, more importantly, have determined when and where these factors are required for completion of ductal outgrowth and branch patterning. The reason for the success of the mouse mammary gland model is undoubtedly the suitability of the postnatal mammary gland to experimental manipulation. The gland itself is very amenable to investigation and the combination of genetic modification with accessibility to the tissue has allowed an impressive number of studies to inform biology. Excision of the rudimentary epithelial structure postnatally allows genetically modified tissue to be readily transplanted into wild type stroma or vice versa, and has thus defined the contribution of each compartment to particular phenotypes. Similarly, whole gland transplantation has been used to definitively discern local effects from indirect systemic effects of various growth factors and hormones. While appreciative of the power of these tools and techniques, we are also cognizant of some of their limitations, and we discuss some shortcomings and future strategies that can overcome them.

Pipeline for contraceptive development

The high rates of unplanned pregnancy reflect an unmet need for effective contraceptive methods for women, especially for individuals with health risks such as obesity, diabetes, hypertension, and other conditions that may contraindicate use of an estrogen-containing product. Improvements in safety, user convenience, acceptability, and availability of products remain important goals of the contraceptive development program. Another important goal is to minimize the impact of the products on the environment. Development of new methods for male contraception has the potential to address many of these issues of safety for women who have contraindications to effective contraceptive methods but want to protect against pregnancy. It would also address a huge unmet need for men who want to control their fertility. Products under development for men would not introduce ecotoxic hormones into the water system.

Risk assessment of down-the-drain chemicals at large spatial scales: Model development and application to contaminants originating from urban areas in the Saint Lawrence River Basin

Chemicals released into freshwater systems threaten ecological functioning and may put aquatic life and the health of humans at risk. We developed a new contaminant fate model (CFM) that follows simple, well-established methodologies and is unique in its cross-border, seamless hydrological and geospatial framework, including lake routing, a critical component in northern environments. We validated the model using the pharmaceutical Carbamazepine and predicted eco-toxicological risk for 15 pharmaceuticals in the Saint-Lawrence River Basin, Canada. The results indicated negligible to low environmental risk for the majority of tested chemicals, while two pharmaceuticals showed elevated risk in up to 13% of rivers affected by municipal effluents. As an integrated model, our CFM is designed for application at very large scales with the primary goal of detecting high risk zones. In regulatory frameworks, it can help screen existing or new chemicals entering the market regarding their potential impact on human and environmental health. Due to its high geospatial resolution, our CFM can also facilitate the prioritization of actions, such as identifying regions where reducing contamination sources or upgrading treatment plants is most pertinent to achieve targeted pollutant removal or to protect drinking water resources.

Human Health Relevance of Pharmaceutically Active Compounds in Drinking Water

In Canada, as many as 20 pharmaceutically active compounds (PhACs) have been detected in samples of treated drinking water. The presence of these PhACs in drinking water raises important questions as to the human health risk posed by their potential appearance in drinking water supplies and the extent to which they indicate that other PhACs are present but have not been detected using current analytical methods. Therefore, the goal of the current investigation was to conduct a screening-level assessment of the human health risks posed by the aquatic release of an evaluation set of 335 selected PhACs. Predicted and measured concentrations were used to estimate the exposure of Canadians to each PhAC in the evaluation set. Risk evaluations based on measurements could only be performed for 17 PhACs and, of these, all were found to pose a negligible risk to human health when considered individually. The same approach to risk evaluation, but based on predicted rather than measured environmental concentrations, suggested that 322 PhACs of the evaluation set, when considered individually, are expected to pose a negligible risk to human health due to their potential presence in drinking waters. However, the following 14 PhACs should be prioritized for further study: triiodothyronine, thyroxine, ramipril and its metabolite ramiprilat, candesartan, lisinopril, atorvastatin, lorazepam, fentanyl, atenolol, metformin, enalaprilat, morphine, and irbesartan. Finally, the currently available monitoring data for PhACs in Canadian surface and drinking waters was found to be lacking, irrespective of whether their suitability was assessed based on risk posed, predicted exposure concentrations, or potency.